Current Report Filing (8-k)
November 12 2020 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
November
12, 2020
AYTU
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-38247
|
47-0883144
|
(State or other
jurisdiction of incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
373
Inverness Parkway, Suite 206
Englewood,
CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-6580
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section
12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange
on
which registered
|
Common
Stock, par value $0.0001 per share
|
AYTU
|
The
NASDAQ Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
November 12, 2020, the Company issued a press release announcing
the Company’s financial results for the three months ended
September 30, 2020. A copy of the press release is attached as
Exhibit 99.1 and incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the
information in the press release attached as Exhibit 99.1 hereto
shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), nor shall such information be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
Exhibit
|
|
Description
|
|
|
Press release
dated November 12, 2020
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
AYTU BIOSCIENCE,
INC.
|
|
|
|
|
|
|
|
|
|
|
Date: November 12,
2020
|
|
By:
|
/s/ Joshua R.
Disbrow
|
|
|
|
|
Joshua R.
Disbrow
|
|
|
|
|
Chief Executive
Officer
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2024 to May 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From May 2023 to May 2024